DDInter1340 DDInter224
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment.
Omeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bosutinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Urinary tract disorder
Urinary tract disorder {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Omeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Urinary tract disorder
Urinary tract disorder {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bosutinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Omeprazole {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Omeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Omeprazole (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Bosutinib (Compound)
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Omeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)
Omeprazole (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)
Omeprazole (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Omeprazole (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Omeprazole (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Rilpivirine (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)